Medical Device Registration in Southeast Asia: ASEAN Harmonization & Country Guide

Why Southeast Asia Matters for Medical Device Manufacturers

Southeast Asia is one of the fastest-growing medical device markets in the world. The combined population of the ten ASEAN member states exceeds 680 million people. Healthcare spending across the region has been growing at 9–12% annually, driven by aging demographics, expanding insurance coverage, rising chronic disease burden, and government investment in healthcare infrastructure.

The ASEAN medical device market was valued at approximately USD 12–14 billion in 2025 and is projected to reach USD 20–22 billion by 2030. Indonesia alone, with over 280 million people, represents one of the largest under-penetrated medical device markets globally. Thailand and Singapore serve as regional hubs for medical tourism and advanced healthcare. Vietnam and the Philippines are rapidly modernizing their hospital systems.

For manufacturers already selling in the US and EU, Southeast Asia offers a logical next step for geographic expansion. But the regulatory landscape here is unlike what you are accustomed to. There is no single regulatory authority. There is no single registration. Each country operates its own national regulatory authority (NRA) with its own classification system, dossier requirements, timelines, and fees — even though the ASEAN Medical Device Directive (AMDD) was designed to harmonize the framework.

This guide covers the ASEAN harmonization framework, then walks through the six largest markets country by country: Singapore, Malaysia, Thailand, Indonesia, the Philippines, and Vietnam. It addresses classification systems, registration pathways, local representative requirements, timelines, fees, IVD-specific considerations, post-market obligations, and the practical realities of navigating this region.

The ASEAN Medical Device Directive (AMDD)

What the AMDD Is

The ASEAN Medical Device Directive is a framework agreement adopted by the ASEAN member states to harmonize medical device regulation across the region. It was first endorsed in 2014 by the ASEAN Economic Ministers and has been progressively implemented — at varying speeds — by individual member states.

The AMDD is modeled on the Global Harmonization Task Force (GHTF) framework, which also influenced the IMDRF (International Medical Device Regulators Forum). If you are familiar with GHTF/IMDRF principles — risk-based classification, essential principles of safety and performance, a structured pre-market submission dossier, and post-market surveillance obligations — you will recognize the AMDD's architecture.

The AMDD covers:

• Definition of a medical device — aligned with the GHTF definition
• Risk-based classification — four classes (A, B, C, D) based on GHTF classification rules
• Essential Principles of Safety and Performance — requirements that all devices must meet
• Conformity assessment procedures — based on device risk class
• Common Submission Dossier Template (CSDT) — a standardized dossier format
• Labeling requirements
• Post-market surveillance and vigilance requirements

What the AMDD Is NOT

The AMDD is not a regulation. It is a directive — a framework that each member state must transpose into its own national law. This is a critical distinction. Unlike the EU MDR, which is a regulation directly applicable in all member states, the AMDD relies on each country to implement its provisions through national legislation. This means:

• Implementation timelines vary. Singapore adopted AMDD-aligned regulation years before some other member states.
• Interpretation varies. Each NRA may add national requirements on top of the AMDD baseline.
• Enforcement varies. The capacity and resources of NRAs differ significantly across the region.
• Not all AMDD provisions have been adopted by all countries. Some member states are still in transition.

The result is a framework that is harmonized in theory but fragmented in practice. As a manufacturer, you cannot prepare a single dossier and submit it across all ASEAN countries without modification. But the CSDT gives you a common starting point, and understanding the AMDD framework helps you build a dossier that can be adapted efficiently for multiple markets.

The Common Submission Dossier Template (CSDT)

The CSDT is the AMDD's standardized format for pre-market submission dossiers. It is structured into chapters that align with GHTF/IMDRF guidance:

CSDT Chapter	Content
Chapter 1	Regional administrative information (country-specific forms, local representative details, regulatory status in other countries)
Chapter 2	Table of contents
Chapter 3	Executive summary (device description, intended purpose, regulatory history)
Chapter 4	Essential Principles checklist — how the device meets each applicable Essential Principle, with references to supporting evidence
Chapter 5	Device description and specifications (materials, design, principles of operation, accessories, variants)
Chapter 6	Labeling (labels, instructions for use, packaging)
Chapter 7	Risk analysis summary (typically ISO 14971-based risk management documentation)
Chapter 8	Evidence of design verification and validation (bench testing, biocompatibility, electrical safety, software verification, etc.)
Chapter 9	Clinical evidence (clinical evaluation, clinical investigation data if applicable)
Chapter 10	Manufacturing information (quality management system evidence, sterilization validation if applicable)
Chapter 11	Other relevant documentation (stability data, shelf life studies, etc.)

Practical Notes on the CSDT

• Chapter 1 is always country-specific. Even with a common dossier, you will rewrite Chapter 1 for each country because it contains national application forms, local representative details, and country-specific administrative requirements.
• Not all countries require all chapters for all device classes. Class A devices (lowest risk) generally require a simplified submission. Class D devices (highest risk) require the full dossier.
• Some countries accept the CSDT directly; others require their own format. Singapore (HSA) fully accepts the CSDT. Indonesia (Kemenkes) has its own submission format but accepts CSDT-structured dossiers with additional national requirements. Thailand requires documents to be translated or at minimum summarized in Thai for some sections.
• Quality system evidence is a common sticking point. Most ASEAN countries require ISO 13485 certification. Some accept the manufacturer's ISO 13485 certificate directly; others require additional factory audits or QMS documentation.

Practical tip: Build your master dossier in CSDT format from the start, even if your first ASEAN market does not require it. The upfront investment pays for itself when you expand to additional countries. Structure your technical file so that Chapters 3–11 can be reused with minimal modification, and keep Chapter 1 as a modular, country-specific section.

ASEAN Medical Device Classification

The AMDD adopts a four-class system based on GHTF classification rules:

Class	Risk Level	Examples	Regulatory Control
Class A	Low risk	Tongue depressors, reusable surgical instruments, bandages, wheelchairs	Manufacturer self-declaration (some countries) or notification
Class B	Low-moderate risk	Hypodermic needles, suction equipment, powered wheelchairs, ultrasound diagnostic devices	Pre-market notification or registration
Class C	Moderate-high risk	Ventilators, bone fixation plates, hemodialysis equipment, infusion pumps	Full pre-market review
Class D	High risk	Cardiac stents, pacemakers, breast implants, total joint replacements, HIV diagnostic tests	Full pre-market review with clinical evidence

Classification is determined by 16 rules that consider: whether the device is invasive, the duration of contact, whether the device is active, and the body system affected. The rules are based on GHTF Study Group 1 guidance and will be familiar to anyone who has worked with the EU MDR classification system (which shares the same GHTF heritage).

Key differences from other systems:

• ASEAN Class A/B/C/D maps roughly to EU MDR Class I/IIa/IIb/III, but the correspondence is not exact. Always classify independently under ASEAN rules.
• Some countries have not fully adopted all 16 AMDD classification rules. Check the specific national classification system before assuming your ASEAN classification applies.
• IVDs may follow a separate classification scheme in some countries (discussed in the IVD section below).

Country-by-Country Registration Guide

Singapore — Health Sciences Authority (HSA)

Singapore is the most mature and predictable medical device regulatory environment in ASEAN. The HSA is widely regarded as a reference NRA in the region, and a Singapore registration can sometimes accelerate or simplify registrations in other ASEAN markets.

Governing legislation: Health Products Act (Cap. 122D) and Health Products (Medical Devices) Regulations 2010

Classification system: ASEAN-harmonized four-class system (A, B, C, D) based on GHTF rules. Singapore was among the first ASEAN states to implement the full AMDD classification system.

Registration pathways:

Device Class	Pathway	Description
Class A	Dealer's License only	No product registration required. The dealer (importer/distributor) must hold a Dealer's License from HSA. Class A devices are listed but not individually registered.
Class B	Registration (Immediate/Expedited/Full evaluation)	Requires product registration. Immediate or Expedited pathways available if the device has prior approval from a recognized reference regulatory agency.
Class C	Registration (Expedited/Full evaluation)	Full CSDT-based submission. Expedited pathway available with reference agency approval.
Class D	Registration (Full evaluation)	Full evaluation required with comprehensive clinical evidence. Expedited pathway available in limited circumstances.

Abridged evaluation routes: HSA offers expedited review for devices already approved by reference regulatory agencies. The recognized reference agencies include:

• US FDA
• EU (CE marking under MDR/MDD)
• Health Canada
• Australia TGA
• Japan PMDA

If your device is cleared or approved by one or more of these agencies, you may qualify for the Expedited review route, which significantly reduces review time and the depth of HSA's evaluation.

Local representative requirement: A Singapore-based company must hold a Dealer's License and act as the local responsible person. Foreign manufacturers cannot register devices directly — you need a licensed local dealer.

Timeline:

Route	Typical Timeline
Class A (Dealer's License)	1–4 weeks
Class B (Immediate — reference agency)	1–2 weeks
Class B (Expedited — reference agency)	3–5 months
Class B (Full evaluation)	7–10 months
Class C/D (Expedited)	4–8 months
Class C/D (Full evaluation)	10–14 months

Fees (approximate, as of 2025/2026):

Fee Type	Amount (SGD)
Dealer's License (new application)	SGD 250
Dealer's License (annual renewal)	SGD 210
Class B registration (Full)	SGD 2,220
Class C registration (Full)	SGD 9,840
Class D registration (Full)	SGD 14,800
Expedited evaluation surcharge	50% of base evaluation fee
Variation (major)	SGD 1,100–7,400

Submission platform: As of July 14, 2025, HSA replaced the legacy MEDICS system with the new SHARE (Singapore Health Product Access and Regulatory E-System) platform. All new product registrations, Class A notifications, Dealer's Licence applications, change notifications, cancellations, Free Sale Certificates, and Special Access Route submissions are now filed through SHARE. Companies must access SHARE via Corppass. MEDICS is no longer available. If you have ongoing applications that were migrated from MEDICS, pending Input Requests were re-sent through SHARE — check your SHARE inbox.

Updated fees (as of 2025/2026):

HSA revised its fee structure alongside the SHARE transition. The current structure separates a base application fee from an evaluation fee:

Fee Type	Amount (SGD)
Application fee (all classes)	SGD 560
Class B evaluation — Abridged (reference agency)	SGD 2,010
Class B evaluation — Full	SGD 2,220
Class C evaluation — Abridged	SGD 3,900
Class C evaluation — Full	SGD 9,840
Class D evaluation — Abridged	SGD 6,250
Class D evaluation — Full	SGD 14,800
Dealer's Licence (new application)	SGD 250
Dealer's Licence (annual renewal)	SGD 210
Expedited evaluation surcharge	50% of base evaluation fee
Variation (major)	SGD 1,100–7,400

HSA's WHO Maturity Level 4 recognition: In March 2026, HSA became the first national regulatory authority in the world to attain the highest WHO Maturity Level (ML4) for medical device regulatory systems. This recognition makes HSA a global reference authority that other regulators worldwide can rely upon. For manufacturers, this means HSA approvals carry even greater weight when used as reference agency evidence in other ASEAN submissions and globally.

Cybersecurity Labelling Scheme for Medical Devices (CLS(MD)): Singapore launched the CLS(MD) in October 2024 as a joint initiative between CSA, MOH, HSA, and Synapxe. This voluntary scheme rates internet-connected medical devices across four levels of cybersecurity robustness. The scheme applies to devices that handle personal identifiable information (PII) or clinical data, or that connect to other devices and systems via wired or wireless communication protocols. During the initial nine-month trial, 47 devices were evaluated. Labels are valid for up to three years. While the CLS(MD) operates independently from HSA's product registration process, manufacturers of connected medical devices should consider the scheme as part of their Singapore market strategy, as cybersecurity transparency is increasingly expected by healthcare institutions.

SaMD and AI/ML regulatory framework: HSA has issued comprehensive SaMD guidance (GL-04, Revision 4, December 2025) aligned with IMDRF principles and covering the total product lifecycle approach. The guidance includes a Predetermined Change Management Plan (CMP) pathway that allows manufacturers to anticipate routine software updates and include supporting documentation in advance. If accepted into the CMP, future versions of related SaMD products can reference previously submitted documents, streamlining the review process. HSA also updated GN-21 (Guidance on Change Notification, Revision 6, July 2025) with a new flowchart specifically for Machine Learning-enabled Medical Devices (MLMDs) and a new change type (6E) for submitting UDI data elements for registered devices.

Key considerations for Singapore:

• HSA is efficient and transparent. Deficiency questions are specific and answerable. This is a regulatory authority that works well with manufacturers who submit well-prepared dossiers.
• The Dealer's License requirement means you must have a commercial relationship with a local dealer before you can register. Choose your dealer carefully — they become the legal entity responsible for the product in Singapore.
• Post-market requirements include adverse event reporting (within prescribed timelines), Field Safety Corrective Actions, and periodic safety update reporting for Class C and D devices.
• Singapore accepts the CSDT format directly, making it an ideal first ASEAN market for testing your dossier structure.
• HSA's expanded economic role now includes aligned pathways with the Agency for Care Effectiveness and public healthcare clusters for products addressing Singapore's disease priority areas (cardiovascular, diabetes, metabolic disorders). This can facilitate simultaneous regulatory approval, health technology assessment, and clinical development.

Practical tip: If you do not yet have a presence in Southeast Asia, Singapore is the best starting point. The regulatory process is transparent, timelines are predictable, and HSA recognition carries weight with other ASEAN regulators. Use Singapore to validate your CSDT-structured dossier before adapting it for other markets.

Malaysia — Medical Device Authority (MDA)

Malaysia has a well-established medical device regulatory system under the Medical Device Authority (MDA), operating within the Ministry of Health.

Governing legislation: Medical Device Act 2012 (Act 737) and Medical Device Regulations 2012

Classification system: ASEAN-harmonized four-class system (A, B, C, D). Malaysia was an early adopter of the AMDD classification rules.

Registration pathways:

Device Class	Pathway	Description
Class A	Registration (basic)	Simplified registration with basic documentation. No detailed technical evaluation.
Class B	Registration (standard)	Standard registration with CSDT-based dossier. MDA reviews technical documentation.
Class C	Registration (standard/priority)	Full dossier review including clinical evidence. Priority review may be available for devices with prior approval from recognized agencies.
Class D	Registration (standard/priority)	Full dossier review with comprehensive clinical evidence and detailed safety assessment.

Conformity Assessment Body (CAB) route: Malaysia uses a unique conformity assessment approach. For Class C and D devices, a MDA-recognized Conformity Assessment Body conducts the technical review of the dossier and issues a conformity assessment certificate. This is analogous to the EU's Notified Body system but operates within a national framework. MDA then reviews the CAB's report and makes the final registration decision.

Local representative requirement: A Malaysian Authorized Representative (MAR) is required for all foreign manufacturers. The MAR must be a company registered in Malaysia and must be listed on the device registration. The manufacturer must provide the MAR with a Letter of Authorization.

Timeline:

Route	Typical Timeline
Class A	1–3 months
Class B	3–6 months
Class C (priority review)	6–9 months
Class C (standard)	9–14 months
Class D (priority review)	8–12 months
Class D (standard)	12–18 months

Fees (approximate, as of 2025/2026):

Fee Type	Amount (MYR)
Class A registration	MYR 200–500
Class B registration	MYR 1,000–2,000
Class C registration	MYR 3,000–5,000
Class D registration	MYR 5,000–8,000
Establishment License (annual)	MYR 300–1,000
CAB assessment fee (Class C/D)	MYR 5,000–25,000 (varies by CAB and device complexity)

Note: CAB fees are separate from MDA registration fees and are paid directly to the Conformity Assessment Body. They can be substantial for complex Class D devices.

Submission platform: All device registrations and lifecycle management are handled through the MeDC@St 2.0+ (Medical Device Centralised Online System) portal. From May 2025, product classification became fully online — applicants submit classification requests digitally and receive e-classification letters through the same platform. Ensure your Authorized Representative maintains an active MeDC@St account and uses the newest file formats.

Updated fees (as of January 2026):

MDA revised its fee structure under the Medical Device (Amendment) Regulations 2025 [P.U.(A) 330], effective January 1, 2026:

Fee Type	Amount (MYR)
Class A application fee	MYR 500 (increased from MYR 100)
Class A registration fee	MYR 750 (newly introduced)
Class B — CAB fee	MYR 1,300
Class B — MDA (MOH) fee	MYR 1,250
Class C — CAB fee	MYR 1,300
Class C — MDA (MOH) fee	MYR 2,500
Class D — CAB fee	MYR 1,300
Class D — MDA (MOH) fee	MYR 3,750
Combination Device — CAB fee	MYR 1,300
Combination Device — MDA (MOH) fee	MYR 5,750
Establishment License (annual)	MYR 300–1,000
License transfer	~MYR 500 per device registration ID

Note: The Class A fee increase from MYR 100 to MYR 500 (plus the new MYR 750 registration fee) reflects MDA's cost-recovery model and expanded post-market surveillance commitments. Plan budgets accordingly.

Expanded list of recognized regulatory authorities (2025): MDA Circular Letter Number 2 Year 2025 formally added Singapore HSA and Thailand FDA to the list of recognized reference regulatory authorities. The full list now includes eight agencies:

1. US FDA
2. EU Notified Bodies (CE marking under MDR/IVDR)
3. Health Canada
4. Australia TGA
5. Japan PMDA/MHLW
6. UK MHRA
7. Singapore HSA
8. Thailand FDA

Devices with approvals from any of these agencies are eligible for the Verification Assessment pathway — a more succinct and efficient review alternative to full conformity assessment. The Verification route typically takes approximately 30 working days versus 60 working days for full conformity assessment.

Import permit requirements (effective January 2, 2026): MDA now requires import permits for medical devices. Importers must activate their ePermit account and file import permits at least one week before shipment. MDA has also clarified the Import-for-Re-Export (IRE) pathway, which allows temporary importation of a medical device into Malaysia only for the purpose of re-exporting it to another country, without placing the device on the Malaysian market.

MDSAP affiliate membership: In 2025, MDA was recognized as an affiliate member of the Medical Device Single Audit Program (MDSAP). While MDA does not yet formally accept MDSAP audit reports as a substitute for its own assessment, this affiliate membership signals increasing alignment with global QMS harmonization frameworks.

Key considerations for Malaysia:

• The CAB system adds a layer of review but can be efficient if you select a CAB familiar with your device type. The Verification route (abridged pathway through a CAB) significantly reduces timelines for devices with approvals from recognized authorities — CAB review takes approximately 2–4 months upon submission, and MDA review can be shorter than historical norms because the CAB assessment serves as the primary review step.
• Malaysia requires an Establishment License for all entities involved in the medical device supply chain (manufacturers, importers, distributors). Your local partner must hold the appropriate license.
• MDA has been progressively increasing its post-market surveillance capacity, including adverse event reporting requirements and periodic review of registered devices.
• For devices with prior approval from recognized regulatory agencies (now eight agencies including HSA and Thai FDA), MDA offers expedited review via the Verification Assessment pathway.
• All labeling must include certain Malaysia-specific information, including the MDA registration number and the MAR's details.
• UDI implementation is on MDA's roadmap. Monitor announcements for timeline requirements — e-labeling and UDI are listed among MDA's 2026 priorities.
• Regulatory sandbox: MDA launched its first regulatory sandbox for medical devices in 2025, allowing controlled evaluation of novel devices or technologies that may not fit neatly into existing classification frameworks.

Thailand — Thai Food and Drug Administration (Thai FDA)

Thailand has a large and growing medical device market, driven by its status as a medical tourism hub, government universal healthcare coverage, and an expanding hospital infrastructure. The Thai FDA, under the Ministry of Public Health, is the regulatory authority for medical devices.

Governing legislation: Medical Device Act B.E. 2551 (2008), as amended, and associated ministerial notifications

Classification system: Thailand uses a three-tier risk classification system that does not directly mirror the AMDD four-class system:

Thai FDA Category	Risk Level	ASEAN Equivalent	Regulatory Control
General Medical Devices	Low risk	Roughly Class A/B	Notification (listing)
Controlled Medical Devices	Moderate risk	Roughly Class B/C	Notification with documentation
Specially Controlled Medical Devices	High risk	Roughly Class C/D	Full pre-market registration (license)

This three-tier system is a significant divergence from the AMDD four-class model and creates classification mapping challenges. Thailand has been working toward adopting the AMDD four-class system, but as of 2026, the three-tier system remains in effect for most device categories.

Registration pathways:

Device Category	Requirement	Description
General	Notification	Submit notification form and basic product information. No technical dossier review.
Controlled	Notification with documentation	Submit notification with supporting technical documentation. Thai FDA may review.
Specially Controlled	Registration license	Full pre-market review. CSDT-aligned dossier required. Clinical evidence required for higher-risk devices.

Local representative requirement: A Thai-registered company must act as the importer and license holder. Foreign manufacturers cannot hold Thai FDA registrations directly. The Thai importer submits the registration and is legally responsible for the product in Thailand. The relationship between the manufacturer and the Thai importer is formalized through a Power of Attorney or Letter of Authorization.

Language requirements: This is a practical hurdle. Thai FDA requires documents to be in Thai or accompanied by certified Thai translations. For Specially Controlled Devices, the technical dossier may be submitted in English, but key sections (labeling, instructions for use, and certain summary documents) must be in Thai. Requirements have evolved — check current guidance, as Thailand has been liberalizing its language policy for technical documents.

Timeline:

Category	Typical Timeline
General (notification)	1–4 weeks
Controlled (notification with docs)	1–3 months
Specially Controlled (registration)	6–18 months

The wide range for Specially Controlled devices reflects the reality: straightforward devices with strong reference agency approvals may clear in 6–9 months, while novel or complex devices can take 12–18 months or longer if deficiency questions arise.

Fees (approximate, as of 2025/2026):

Fee Type	Amount (THB)
General device notification	THB 500–2,000
Controlled device notification	THB 1,000–5,000
Specially Controlled device license	THB 5,000–20,000
License renewal (every 5 years)	THB 3,000–10,000
Import license (per shipment or annual)	THB 1,000–5,000

Government fees in Thailand are relatively low compared to other ASEAN markets. However, the costs of Thai translation, local representative services, and the extended timelines for Specially Controlled devices can add up.

Four-class AMDD transition: Thailand has been actively working toward adopting the full AMDD four-class system. Draft regulations align the new classification as follows:

New AMDD Class	Risk Level	Current Thai Category	Registration Requirement
Class I	Low risk	General	Listing before import/marketing
Class II	Low-moderate risk	General/Controlled	Notification with technical dossier (CSDT format)
Class III	Moderate-high risk	Controlled/Specially Controlled	Notification with CSDT dossier
Class IV	High risk	Specially Controlled	Approved license with full CSDT dossier

Under the draft regulations, Class I sterile and measuring devices will require submission of testing reports. Class II, III, and IV devices require submission of technical dossiers per the ASEAN CSDT format. While the three-tier system remains in effect as of early 2026, manufacturers should begin preparing for the transition by classifying devices under both the current and forthcoming systems.

New labeling regulation B.E. 2568 (2025): In December 2025, Thailand's Ministry of Public Health issued the final Notification on Rules, Procedures, and Conditions for Medical Device Labeling and Instructions for Use (IFU). This regulation takes effect on June 20, 2026, with a two-year transition period (until June 20, 2028) during which labels compliant with the previous B.E. 2563 (2020) requirements remain valid. Key provisions include:

• Product categorization: Devices are formally divided into four categories: home-use devices, professional-use devices, software as a medical device (SaMD), and reusable surgical instruments/accessories — each with defined labeling and IFU obligations.
• Language requirements refined: Home-use devices require comprehensive Thai-language labeling and manuals. Professional-use devices may use Thai or English.
• Electronic IFU (e-labeling) confirmed: For professional-use devices, electronic IFUs (e.g., via QR codes) are permitted, reducing packaging costs and paper waste.
• SaMD-specific labeling: Software devices must display required regulatory information electronically within the software itself (e.g., on a splash screen or "About" page), including UDI where applicable.
• 120-day import buffer: Importers are granted a grace period — basic labeling must be present at the customs checkpoint (in Thai or English), but importers have up to 120 days after customs release to ensure full, compliant labeling is attached before the product is sold. This is reduced from the previous 180-day grace period.

Electronic change notification system (2026): Thai FDA launched a new electronic system for submitting post-approval changes to medical device licenses, making regulatory updates fully digital. The system covers labeling updates, manufacturer details, product specifications, and more. Updated guidelines introduce clearer categorization of major, minor, and auto-approved changes, helping companies better plan regulatory strategies.

Key considerations for Thailand:

• The classification mapping challenge is real. Do not assume your ASEAN classification translates directly to a Thai FDA category. Work with your local partner to confirm the correct Thai classification based on the ministerial notifications that define which devices fall into each category. Prepare for the forthcoming four-class transition by maintaining classification documentation under both the current and AMDD systems.
• Thai FDA has been actively modernizing. Electronic submission systems have been introduced, and the agency has made efforts to reduce review timelines for devices with strong reference agency approvals. The 2026 electronic change notification system is part of this digital transformation.
• Thailand requires Good Manufacturing Practice (GMP) compliance. For domestically manufactured devices, Thai FDA conducts facility inspections. For imported devices, ISO 13485 certification is generally accepted, but Thai FDA reserves the right to request additional manufacturing information.
• Post-market requirements include adverse event reporting and product recall procedures. The Thai FDA's vigilance system has become increasingly active.
• Registration licenses for Specially Controlled devices must be renewed every 5 years.
• Standalone software recognition: Thai FDA issued three notifications in B.E. 2569 (2026) adjusting the scope of establishment registration to cover notification of storage locations for medical devices in the form of standalone software. This is part of Thailand's effort to address digital health technologies within its regulatory framework.
• MDA recognition of Thai FDA: Malaysia's MDA added Thailand FDA to its list of recognized regulatory authorities in 2025. Thai FDA-approved devices are now eligible for Malaysia's Verification (abridged) pathway, and vice versa, under the Malaysia-Thailand Regulatory Reliance Pilot (February–April 2026).

Practical tip: The Thai market is large enough to justify the investment in registration, but the language requirements and classification mapping require local expertise. Engage a Thai regulatory consultant or work through an experienced local distributor who has a track record of successful registrations with the Thai FDA. Begin planning for the June 2026 labeling deadline now — review your portfolio for home-use versus professional-use classification, assess translation needs, and implement digital access for e-labeling where permitted.

Indonesia — Ministry of Health (Kemenkes)

Indonesia is the largest market in ASEAN by population and one of the most challenging to navigate from a regulatory perspective. The regulatory authority is the Directorate General of Pharmaceuticals and Medical Devices within the Ministry of Health (Kementerian Kesehatan, or Kemenkes).

Governing legislation: Government Regulation No. 5 of 2024 on Medical Devices (replacing prior regulations), Minister of Health Regulation on Medical Device Distribution, and associated implementing regulations.

Indonesia's regulatory framework has undergone significant reform in recent years. The government has been working to align its system with the AMDD while simultaneously addressing domestic priorities such as local content requirements and domestic manufacturing promotion.

Classification system: Indonesia has adopted the AMDD-aligned four-class system (A, B, C, D), though the national classification lists may differ from a purely rules-based AMDD classification in some cases. Devices are classified based on risk and are further categorized by the Kemenkes classification database.

Class	Risk Level	Registration Type
Class A	Low risk	Notification (Pemberitahuan)
Class B	Low-moderate risk	Registration (Pendaftaran) with technical review
Class C	Moderate-high risk	Registration with full technical evaluation
Class D	High risk	Registration with full technical evaluation and clinical review

Registration pathways and key compliance pillars:

Marketing a medical device in Indonesia requires navigating three interconnected compliance pillars:

1. IDAK (Izin Distribusi Alat Kesehatan) — Distribution License: The IDAK is the company-level distribution license that the local entity must hold. Foreign manufacturers cannot hold an IDAK directly — they must either partner with a local distributor company or establish a Foreign Owned Company (PT PMA, which requires an investment threshold of approximately IDR 10 billion / ~USD 611,000). IDAK is valid for 5 years and must be renewed 9 months before expiration. IDAK is the successor to the older IPAK (Izin Penyalur Alat Kesehatan) and SDAK names. IDAK is categorized by product type: radiation electronic medical devices, non-radiation electronic medical devices, sterile non-electronic medical devices, non-sterile non-electronic medical devices, and IVDs. Distributors must also hold a permanent business license under KBLI 46691 (wholesale trade of medical devices).

2. CDAKB (Cara Distribusi Alat Kesehatan yang Baik) — Good Distribution Practices for Medical Devices: After obtaining the IDAK, the company must obtain CDAKB certification within one year. CDAKB is Indonesia's GDP (Good Distribution Practice) framework for medical devices, covering storage, handling, and distribution requirements. Without CDAKB, a company cannot proceed to product registration.

3. AKL/AKD — Product Registration Numbers: This is the product-specific license:

   • AKL (Alat Kesehatan Luar) — the registration number for imported medical devices
   • AKD (Alat Kesehatan Dalam) — the registration number for domestically manufactured medical devices

   Each device model requires its own AKL/AKD number. The application is submitted through the REGALKES online portal operated by Kemenkes. Upon approval, Kemenkes issues a distribution approval number (NIE — Nomor Izin Edar). Per Minister of Health Regulation No. 62 of 2017, Article 13, each medical device (under one trade name/brand name) may only be registered by one license holder.

The registration workflow in sequence:

1. Establish the Indonesian entity (local distributor or PT PMA subsidiary)
2. Obtain IDAK (distribution license) via the OSS-RBA (Online Single Submission — Risk-Based Approach) platform
3. Obtain CDAKB certification (within 1 year of IDAK)
4. Prepare technical dossier per Kemenkes standards (CSDT-aligned with Indonesian additions)
5. Submit product registration via REGALKES portal for AKL number
6. Upon approval, register the KFA (Katalog Farmasi dan Alat Kesehatan) product code and enter the e-Catalogue system to enable government procurement access
7. Conduct post-market surveillance: adverse event reporting, complaints management, facility maintenance

Local representative requirement: This is critical. Indonesia requires that medical devices be distributed through a licensed Indonesian company holding a valid IDAK and CDAKB. For imported devices, the Indonesian license holder submits the AKL application and is legally responsible for the product. Foreign manufacturers have three main routes to market:

• Partner with an existing licensed local distributor
• Appoint a third-party independent license holder (provides better control over registration and compliance)
• Establish a PT PMA subsidiary (full control but higher investment threshold)

TKDN (Tingkat Komponen Dalam Negeri) — Local Content Requirements: Indonesia has implemented local content requirements for medical devices procured for government healthcare facilities. While these rules primarily affect government procurement rather than registration per se, they have significant commercial implications. Devices with higher local content scores receive preference in government tenders, which represent a large share of the Indonesian medical device market. Some manufacturers have responded by establishing local assembly or manufacturing operations.

Halal certification requirements — Phased mandatory timeline: Indonesia's halal certification framework for medical devices has moved from aspiration to mandatory enforcement under Government Regulation (PP) No. 42 of 2024. The phased implementation timeline is:

Device Class	Mandatory Halal Certification Deadline
Class A	2026
Class B	2029
Class C	2034
Class D and biological products	2039

Halal certification is obtained from BPJPH (Badan Penyelenggara Jaminan Produk Halal — the Indonesian Halal Product Assurance Agency). This applies to all products circulating in Indonesia, including imported medical devices. For devices containing animal-derived materials, this is particularly significant. Failure to obtain halal certification by the mandatory deadline may result in product withdrawal, fines, and license suspension. Additionally, the halal label must be displayed on packaging according to BPJPH rules. Foreign products entering Indonesia must obtain halal certification by October 17, 2026 for the first phase of products covered.

E-labeling (Permenkes No. 11 of 2025): Indonesia now formally recognizes electronic labeling under the updated regulatory framework. However, key labeling requirements including Bahasa Indonesia language, halal marking, and the AKL/AKD number must still appear on physical packaging. The Instructions for Use (IFU) is where most administrative queries (rejections) occur during registration — ensure comprehensive Bahasa Indonesia IFUs for Class B, C, and D devices.

Language requirements: Labeling and instructions for use must be in Bahasa Indonesia.

Timeline:

Class	Typical Timeline
Class A	1–3 months
Class B	3–8 months
Class C	6–14 months
Class D	10–18 months

These timelines are estimates and can vary significantly depending on the completeness of the submission, the current workload at Kemenkes, and whether deficiency questions are issued. Indonesia has been working to streamline its review process, but delays are common, particularly for higher-risk devices.

Fees (approximate, as of 2025/2026):

Fee Type	Amount (IDR)
Class A notification	IDR 500,000–2,000,000
Class B registration	IDR 2,000,000–5,000,000
Class C registration	IDR 5,000,000–10,000,000
Class D registration	IDR 10,000,000–20,000,000
Distribution permit renewal	IDR 2,000,000–10,000,000

Government fees are relatively modest. The real cost in Indonesia is the regulatory complexity, local representative management, translation requirements, and the time investment required to navigate the system.

Key considerations for Indonesia:

• The market is enormous but complex. With 280+ million people and rapidly growing healthcare spending, Indonesia is a priority market for many manufacturers. But the regulatory environment is in active transition, with new regulations being issued and existing ones being revised.
• The CKG (Cek Kesehatan Gratis — Free Health Check) program is a major demand driver. Under President Prabowo Subianto, Indonesia is targeting 130 million health screenings in 2026 (up from 70 million in 2025). This program creates massive demand for diagnostic imaging, point-of-care testing, blood pressure monitors, glucose meters, HPV DNA tests, and respiratory diagnostic equipment. Kemenkes is prioritizing AKL applications for devices that support CKG goals — timing your registration to align with government procurement cycles can be strategically advantageous.
• Local content requirements (TKDN) matter commercially. Even if your device is registered, access to the government hospital market — which is the majority of the healthcare market in Indonesia — may be limited if your device has a low TKDN score.
• The regulatory system is digitalizing. The OSS-RBA platform handles business licensing, the REGALKES portal handles product registration, and the KFA/e-Catalogue system enables government procurement access. These systems are still maturing — expect some process friction and plan for technical issues.
• Factory audit requirements. Kemenkes may require a facility audit or inspection of the manufacturing site for higher-risk devices. ISO 13485 certification is generally accepted as evidence of QMS compliance, but additional documentation may be requested.
• Distribution permit (IDAK) validity. IDAK licenses are valid for 5 years and must be renewed 9 months before expiration. CDAKB must be obtained within 1 year of IDAK issuance. AKL/AKD product registrations are valid for up to 5 years (e-license format).
• Halal certification planning is now urgent. With Class A devices facing a 2026 deadline, manufacturers of low-risk devices need to engage with BPJPH immediately. Even if your device class has a later deadline, beginning the halal assessment process early is advisable given the complexity of supply chain documentation required.
• One license holder per product. Per Permenkes No. 62/2017, each medical device under one trade name may only be registered by one license holder. Multiple registrations or license transfers are not permitted. Choose your Indonesian partner carefully — switching later is extremely difficult.

Practical tip: Indonesia rewards patience and strong local partnerships. The regulatory timeline can be unpredictable, and the relationship between your company and your Indonesian authorized representative is critical. Choose a partner who holds valid IDAK and CDAKB certifications, understands both the regulatory process (REGALKES, OSS-RBA) and the commercial landscape (TKDN, KFA/e-Catalogue, government procurement cycles), and has capacity to manage halal certification requirements. Consider whether an independent third-party license holder may provide better control over your product registration than a distributor who may have competing product lines.

Philippines — Food and Drug Administration Philippines (FDA Philippines)

The Philippines has a growing medical device market served by a regulatory system that has been progressively strengthening over the past decade.

Governing legislation: Republic Act No. 9711 (FDA Act of 2009), Administrative Order No. 2018-0002 (Guidelines on the Licensing and Registration of Medical Devices), and associated implementing rules.

Classification system: The Philippines has adopted an AMDD-aligned four-class system (A, B, C, D). Devices are classified using GHTF-based classification rules, though the FDA Philippines maintains its own classification database and product codes.

Class	Risk Level	Registration Requirement
Class A	Low risk	Notification
Class B	Low-moderate risk	Registration with abbreviated review
Class C	Moderate-high risk	Registration with standard review
Class D	High risk	Registration with full evaluation

Registration pathways:

All medical devices require a Certificate of Product Registration (CPR) or a Certificate of Product Notification (CPN for Class A) from FDA Philippines. The application is submitted through the FDA Philippines online system.

Additionally, establishments involved in the manufacture, importation, distribution, or sale of medical devices must obtain a License to Operate (LTO) from FDA Philippines.

Local representative requirement: An importer or distributor with a valid LTO from FDA Philippines must sponsor the registration. Foreign manufacturers cannot register directly. A Proof of Authorized Distributorship or Authorized Representative agreement is required.

Timeline:

Class	Typical Timeline
Class A (notification)	1–2 months
Class B	3–6 months
Class C	6–12 months
Class D	9–18 months

FDA Philippines has been working to reduce review timelines, particularly for devices with prior approvals from recognized regulatory authorities (FDA US, CE marking, HSA, TGA). An expedited pathway exists for such devices, though its availability and timeline benefits can vary.

Fees (approximate, as of 2025/2026):

Fee Type	Amount (PHP)
Class A notification	PHP 1,000–3,000
Class B registration	PHP 5,000–10,000
Class C registration	PHP 10,000–20,000
Class D registration	PHP 15,000–30,000
LTO (new)	PHP 5,000–15,000
LTO (renewal)	PHP 3,000–10,000
CPR validity	5 years

Published turnaround times (TATs): FDA Philippines has published official target review timelines:

Class	Target Turnaround Time
Class A	24 working days
Class B	80 working days
Class C/D	100 working days
Abridged pathway (ASEAN-approved devices)	20 working days

These are target timelines. Actual review times may exceed these targets, particularly during periods of high submission volume or for complex devices.

Fee suspension: In 2025, FDA Philippines issued DC 2025-0382 temporarily suspending medical device registration fees. This suspension has been extended into 2026. This creates a cost-advantaged window for manufacturers considering Philippine market entry — verify the current status of fee suspension before submission, as it may be reinstated.

Draft IVD regulation: The Philippines has released a draft IVD regulation introducing a modernized framework with a Certificate of IVD Registration (CIVDR) and product risk classification based on AMDD Annex 3. Full implementation is targeted for 2026. Currently, only 8 IVD medical devices are considered registrable in the Philippines. The draft will expand IVD coverage significantly.

Draft Guidelines for Medical Device Software (MDSW): FDA Philippines released draft guidelines covering classification and specific legal and technical requirements for initial and renewal authorization applications of medical device software. The guidelines cover both SaMD and SiMD (excluding software in IVDs). Classification follows AMDD Annex 2 rules with additional SaMD-specific considerations. Class A MDSW initial registration applications must be submitted through the FDA eServices Portal. Abridged pathways may apply for ASEAN-approved devices.

Device grouping (draft 2026): The FDA Philippines Center for Device Regulation (CDRRHR) released a draft circular on "Guidelines on the Qualification Criteria for Grouping of Medical Devices in Product Registration." This framework would allow multiple medical devices to be grouped under a single product registration application where they share the same intended use, manufacturer, and risk classification. Currently, no product grouping is available — each device requires a separate application. If finalized, this will significantly reduce registration burden for manufacturers with large portfolios.

Post-Market Alert System (PMAS) adoption: In 2025, the Philippines formally adopted the PMAS Requirements under Annex 5 of the AMDD through Administrative Order No. 2025-0030. This makes post-market surveillance rules mandatory for all manufacturers, traders, retailers, and distributors. The PMAS framework covers importation/distribution records, complaint records, adverse event reporting criteria and format, and Field Safety Corrective Action reporting. This is a significant step toward AMDD alignment and means post-market obligations in the Philippines are becoming more structured and enforceable.

Key considerations for the Philippines:

• FDA Philippines has limited resources but is actively improving. Review timelines can be unpredictable, but the published TATs provide a benchmark. The abridged pathway for ASEAN-approved devices (20 working days) is particularly attractive.
• The online submission system is functional but can be challenging. System downtime and technical issues are not uncommon. Work with a local partner who is experienced with the system.
• Post-market requirements have been significantly strengthened with the adoption of AMDD Annex 5 PMAS requirements. Ensure your post-market surveillance system covers the new mandatory reporting criteria and formats.
• Language: English is widely used in the Philippines, and regulatory submissions are generally accepted in English. This is a significant advantage compared to some other ASEAN markets.
• Import permit requirements: Some medical devices may require an Import Commodity Clearance in addition to product registration. Certain devices containing or transmitting radiation and those with wireless connectivity require separate FDA permits or registrations from other government agencies. Some specific products must undergo local testing in an accredited Philippine laboratory.
• CPR validity is 5 years, after which renewal is required.
• No product grouping yet. Each device currently requires a separate application and separate CPR. Monitor the draft grouping guidelines — if finalized, this will change the economics of large portfolio registrations.
• CMDN to CMDR transition: Starting October 1, 2024, all manufacturers, traders, exporters, importers, and distributors of medical devices not on the List of Registrable Medical Devices must apply for CMDR (Certificate of Medical Device Registration) for Class B, C, and D devices. Previous CMDN certificates will transition to CMDR upon expiry.

Vietnam — Ministry of Health (MOH)

Vietnam is one of the fastest-growing healthcare markets in ASEAN, with significant government investment in hospital infrastructure and health insurance expansion. The regulatory environment for medical devices has been evolving rapidly.

Governing legislation: Decree No. 98/2021/ND-CP on Medical Device Management (effective January 2022, replacing Decree 36/2016/ND-CP), associated circulars, and implementing guidelines.

The 2021 decree represented a major overhaul of Vietnam's medical device regulatory framework, introducing changes to classification, registration requirements, and post-market obligations.

Classification system: Vietnam has adopted an AMDD-aligned four-class system (A, B, C, D). Devices are classified using GHTF-based rules, and the classification is confirmed by the Department of Medical Equipment and Health Works (DMEHW) under the Ministry of Health.

Class	Risk Level	Registration Requirement
Class A	Low risk	Classification number (notification)
Class B	Low-moderate risk	Registration number (dossier review by local authority)
Class C	Moderate-high risk	Marketing authorization (dossier review by MOH)
Class D	High risk	Marketing authorization (full review by MOH)

Registration pathways:

Under Decree 98/2021, the registration pathway depends on device class:

• Class A and B: These devices are managed at the provincial level. The importer submits a classification dossier to the local Department of Health (DOH), which issues a classification number (Class A) or registration number (Class B).
• Class C and D: These devices require marketing authorization from the Ministry of Health at the national level. A full technical dossier is required, aligned with CSDT principles.

This decentralized approach for lower-risk devices can be efficient but introduces variability depending on which provincial authority reviews the dossier.

Local representative requirement: A Vietnamese-licensed company must serve as the importer and applicant. Foreign manufacturers require a Vietnamese authorized representative to submit registrations. A Letter of Authorization from the manufacturer is required.

Language requirements: Vietnam requires Vietnamese translations for key documents, including labeling, instructions for use, and certain summary documents. Technical data may be submitted in English with Vietnamese summaries for some sections, but requirements can vary. Check current guidance carefully.

Timeline:

Class	Typical Timeline
Class A (classification number)	1–2 months
Class B (registration number)	2–6 months
Class C (marketing authorization)	6–12 months
Class D (marketing authorization)	9–18 months

Fees (approximate, as of 2025/2026):

Fee Type	Amount (VND)
Class A classification number	VND 1,000,000–3,000,000
Class B registration number	VND 3,000,000–8,000,000
Class C marketing authorization	VND 10,000,000–20,000,000
Class D marketing authorization	VND 15,000,000–30,000,000
Import license (per shipment)	VND 500,000–2,000,000

50% fee reduction through December 2026: Vietnam's Ministry of Health announced a temporary 50% reduction in government fees for medical device registration and licensing activities, effective from July 1, 2025 to December 31, 2026. The fee cut applies to new applications for circulation numbers, import/export licenses, testing certificates, and declarations of eligibility. This creates a significant cost-advantaged window for manufacturers entering or expanding in Vietnam. Updated approximate fees (with 50% discount applied):

Fee Type	Discounted Amount (VND)
Class A classification number	VND 500,000–1,500,000
Class B registration number	VND 1,500,000–4,000,000
Class C marketing authorization	VND 5,000,000–10,000,000
Class D marketing authorization	VND 7,500,000–15,000,000
Import license (per shipment)	VND 250,000–1,000,000

Self-declaration pathway risks: In June 2025, Vietnam's MOH hosted a seminar addressing mounting concerns with the medical device self-declaration system for Class A and B devices. Under current regulations, Class A and B devices can be placed on the market immediately upon submission, with classification self-assessed by the applicant. The MOH emphasized that applicants bear full responsibility for the accuracy and integrity of their classification. Incorrect self-declaration can result in enforcement action, product withdrawal, and penalties. This is a real risk — ensure your classification is defensible before relying on the self-declaration pathway.

New labeling requirements (Decree 37/2026/ND-CP): Vietnam issued Decree 37/2026/ND-CP updating medical device labeling requirements, effective January 26, 2026. The decree specifies requirements for circulation numbers, lot numbers, dates, warnings, instructions, and supplementary labels for foreign-language imports.

Registration validity under Decree 98/2021: Under the current framework, most medical device registrations in Vietnam are now valid indefinitely once issued — a significant change from the previous 5-year validity period. However, ongoing post-market obligations continue, and the MOH retains authority to suspend or revoke registrations for cause.

Upcoming six-group quality classification (effective 2027): Vietnam is preparing a new framework that will classify medical devices into six groups based on technical standards and quality certification requirements:

Group	Technical Standard Method	Quality Certification Source	Interpretation
Group 1	Certification	On "Golden List" of recognized authorities	Highest standard; dual stringent requirements
Group 2	Certification	Off Golden List	Strict technical; broader quality source
Group 3	Certification or Assessment	On Golden List	Moderate standards; high quality threshold
Group 4	Certification or Assessment	Off Golden List	Moderate standards; broader quality source
Group 5	Self-declaration or Assessment	On Golden List	Lower standard; high quality threshold
Group 6	Self-declaration or Assessment	Off Golden List	Lowest tier requirements

Devices with marketing authorization from recognized authorities (US FDA, EU, TGA, Health Canada, etc.) automatically meet the high-level quality criterion for upper-tier groups. This framework, once implemented, will create a tiered fast-track system that rewards manufacturers with strong international regulatory approvals.

Key considerations for Vietnam:

• Regulatory framework is in active transition. Decree 98/2021 was a significant change, and implementing circulars and guidance are still being issued. The upcoming six-group quality classification adds another layer of change. This creates uncertainty — what was true six months ago may not be true today.
• The decentralized system for Class A/B devices means your experience will vary depending on the province where your importer is located. Ho Chi Minh City and Hanoi DOHs are generally more experienced than those in smaller provinces. The MOH's crackdown on self-declaration irregularities means that careless classification at the provincial level can trigger enforcement action.
• Import license requirements. Vietnam requires an import license (giay phep nhap khau) for medical devices. This is separate from the product registration and must be obtained for each import shipment or on a periodic basis. Vietnam's MOH has extended import license validity periods in recent updates — check current rules.
• Clinical trials. Vietnam has its own clinical trial requirements for devices that require local clinical data. The Ministry of Health oversees clinical trial approval.
• Free Sale Certificate (FSC) requirement. Vietnam typically requires a Free Sale Certificate or Certificate of Conformity from the country of origin as part of the registration dossier.
• Marketing authorization validity is now indefinite under Decree 98/2021 (changed from the previous 5-year term), though post-market obligations continue.
• The 50% fee reduction window through December 2026 makes this an advantageous time to pursue Vietnam registrations. Factor this into your multi-country ASEAN strategy.

Practical tip: Vietnam's regulatory system is modernizing quickly, but the pace of change means you need up-to-date local intelligence. A regulatory consultant or local partner who actively monitors Vietnamese regulatory developments is essential. Do not rely on information that is more than 6–12 months old. Take advantage of the current fee discount window, but ensure your self-declaration classifications (for Class A/B) are defensible — the MOH is actively investigating irregularities.

Comparative Summary: ASEAN Market Registration at a Glance

Factor	Singapore (HSA)	Malaysia (MDA)	Thailand (Thai FDA)	Indonesia (Kemenkes)	Philippines (FDA PH)	Vietnam (MOH)
Classification	A/B/C/D (AMDD)	A/B/C/D (AMDD)	3-tier (transitioning to AMDD 4-class)	A/B/C/D (AMDD)	A/B/C/D (AMDD)	A/B/C/D (AMDD)
CSDT accepted?	Yes (directly)	Yes (with national additions)	Partially (aligned but with Thai-specific requirements)	Accepted with national additions	Yes (with national additions)	Yes (with national additions)
Submission platform	SHARE (replaced MEDICS July 2025)	MeDC@St 2.0+	Electronic system (2026)	REGALKES / OSS-RBA	FDA eServices Portal	National online system
Local representative required?	Yes (Dealer)	Yes (MAR)	Yes (Thai importer)	Yes (IDAK holder with CDAKB)	Yes (LTO holder)	Yes (Vietnamese importer)
Language	English	English/Malay	Thai for home-use; Thai or English for professional-use	Bahasa Indonesia for labeling/IFU	English	Vietnamese translations required
Typical Class C/D timeline	4–14 months	6–18 months	6–18 months	6–18 months	6–18 months (100 working days target)	6–18 months
Government fee level	Moderate-high	Moderate (Class A increased 2026)	Low	Low	Low (fees currently suspended)	Low (50% discount through Dec 2026)
Reference agency recognition	Strong (FDA, CE, TGA, HC, PMDA)	Strong (8 agencies including HSA, Thai FDA)	Moderate (recognized by MDA)	Limited	Moderate (abridged for ASEAN-approved)	Moderate
Reliance programs	MDA bilateral; WHO ML4 reference	Singapore, Thailand, China pilots; 7 more planned	Malaysia pilot (Feb–Apr 2026)	Part of single submission proposal	AMDD alignment ongoing	Under development
Registration validity	Indefinite (with ongoing obligations)	5 years	5 years	5 years (AKL/AKD)	5 years	Indefinite (Decree 98/2021)
Halal certification	Not required	Not required	Not required	Mandatory (phased: Class A 2026)	Not required	Not required
ISO 13485 required?	Yes	Yes	Yes (for higher-risk)	Yes	Yes	Yes
Regulatory maturity	Very high (WHO ML4)	High (MDSAP affiliate)	Moderate-high (modernizing)	Moderate (evolving)	Moderate (improving)	Moderate (evolving rapidly)

IVD Registration in ASEAN

In vitro diagnostic devices (IVDs) are regulated separately or under special provisions in most ASEAN markets. The AMDD covers IVDs within its framework, but national implementation for IVDs often lags behind general medical devices.

Key IVD Considerations by Market

Singapore: IVDs are regulated under the same Health Products (Medical Devices) Regulations as other medical devices. IVDs follow the AMDD classification system, with Class D IVDs including HIV diagnostics, blood screening tests, and companion diagnostics. The registration process for IVDs mirrors that for other devices of the same class.

Malaysia: IVDs are included in the Medical Device Act 2012. MDA classifies IVDs using AMDD classification rules. Performance evaluation data is required in lieu of or in addition to clinical investigation data for IVDs.

Thailand: IVDs have historically been regulated separately from other medical devices under the Thai FDA framework. Thailand has been working to bring IVD regulation in line with the AMDD, but IVD-specific classification lists and requirements may differ from general medical device rules.

Indonesia: IVDs require distribution permits from Kemenkes, following the same classification framework as other medical devices. IVD-specific requirements include performance evaluation data and, for some high-risk IVDs, local performance validation.

Philippines: IVDs are covered under the FDA Philippines medical device regulations. Classification follows the AMDD system. Performance evaluation evidence is required for Class B and above.

Vietnam: IVDs are covered under Decree 98/2021 and follow the same classification and registration framework as other medical devices. Performance evaluation reports are required, and some IVDs may require local performance validation.

IVD-Specific Documentation

Across ASEAN, IVD registration dossiers should include:

• Performance evaluation report — analytical performance (sensitivity, specificity, precision, linearity, measuring range), clinical performance data, and stability data
• Reference materials and calibration traceability — documentation of metrological traceability
• Specimen requirements — acceptable specimen types, collection, handling, and storage requirements
• Interfering substances — data on known interferences
• For companion diagnostics — evidence linking the IVD to the corresponding therapeutic product

Practical tip: IVD classification in ASEAN can be surprising. Some IVDs that are Class II (moderate risk) in the US may classify as Class D (high risk) in ASEAN — particularly blood screening tests, HIV diagnostics, and tests for high-consequence infectious diseases. Always classify IVDs independently under ASEAN rules and check country-specific IVD classification lists.

Clinical Evidence Requirements

The AMDD requires clinical evidence for all medical devices as part of the Essential Principles of Safety and Performance. However, the depth and type of clinical evidence required varies by device class and by country.

General Framework

Device Class	Clinical Evidence Typically Required
Class A	Minimal. Literature references and existing clinical data usually sufficient.
Class B	Clinical evaluation report based on literature review and/or equivalent device data. Clinical investigation data rarely required.
Class C	Clinical evaluation report with substantive clinical data. May require clinical investigation data for novel devices or new indications.
Class D	Comprehensive clinical evidence. Clinical investigation data often required, particularly for implantable devices or life-sustaining devices.

Country-Specific Clinical Evidence Notes

• Singapore (HSA): Accepts clinical data from international studies (US, EU, Japan, etc.) and typically does not require local clinical data. HSA's clinical evidence expectations are well-documented and align with IMDRF/GHTF principles.
• Malaysia (MDA): Accepts international clinical data. Local clinical data generally not required unless the device is novel or the clinical evidence is insufficient.
• Thailand (Thai FDA): Accepts international clinical data for most devices. May request local clinical data for certain high-risk or novel devices.
• Indonesia (Kemenkes): Has been moving toward requiring local clinical data or local performance validation for certain device categories, particularly higher-risk devices. This is an evolving requirement — monitor closely.
• Philippines (FDA PH): Accepts international clinical data. Local clinical data generally not required.
• Vietnam (MOH): Accepts international clinical data but may require local clinical trials or performance validation for certain high-risk devices or novel technologies.

Clinical Investigation Requirements

If a clinical investigation is required in an ASEAN country, each country has its own clinical trial approval process:

• Ethics committee approval is required in all countries
• National regulatory authority approval is required (HSA in Singapore, Thai FDA in Thailand, Kemenkes in Indonesia, etc.)
• Good Clinical Practice (ISO 14155) compliance is expected across all ASEAN markets
• Clinical trial timelines vary: Singapore typically approves clinical trial applications in 30–60 days; other markets may take 3–6 months or longer
• Insurance and liability requirements vary by country

Post-Market Requirements

All ASEAN countries have post-market surveillance and vigilance requirements, though the maturity and enforcement of these systems varies significantly.

Common Post-Market Obligations

Requirement	Description	Status Across ASEAN
Adverse event reporting	Mandatory reporting of serious adverse events and device malfunctions to the NRA	Required in all 6 countries. Reporting timelines range from 48 hours (for death or serious deterioration) to 30 days (for other reportable events).
Field Safety Corrective Actions (FSCA)	Notification to NRA and affected users when a corrective action is required for safety reasons	Required in all 6 countries. Implementation varies.
Recall reporting	Notification of product recalls to the NRA	Required in all 6 countries.
Post-market surveillance plan	Documented plan for ongoing monitoring of device safety and performance	Required for higher-risk devices in most countries. Singapore and Malaysia have the most specific requirements.
Periodic safety reporting	Periodic reports summarizing post-market safety data	Required for Class C/D devices in Singapore. Required or being implemented in other countries.
Complaint handling	System for receiving and investigating user complaints	Required as part of QMS (ISO 13485). All countries expect this.

Country-Specific Post-Market Notes

• Singapore has the most mature and well-enforced post-market surveillance system in ASEAN. HSA's adverse event reporting system is functional and responsive. Expect engagement from HSA if you report a serious event.
• Malaysia has been strengthening its vigilance system. MDA requires adverse event reporting and has been building its post-market surveillance capacity.
• Thailand requires adverse event reporting and has an active recall notification system. The Thai FDA's vigilance database has been expanding.
• Indonesia is building its post-market surveillance infrastructure. Adverse event reporting is required but enforcement capacity is still developing.
• Philippines requires adverse event reporting through FDA Philippines. The system is functional but capacity is limited.
• Vietnam has introduced post-market surveillance requirements under Decree 98/2021. Implementation is ongoing.

Practical tip: Do not treat ASEAN post-market surveillance as an afterthought. Even if enforcement is uneven, a serious adverse event in any ASEAN market can trigger regulatory action not only locally but also in other markets where your device is registered. Maintain a single global post-market surveillance system and ensure your ASEAN post-market obligations are integrated into it.

ASEAN Mutual Recognition and Harmonization Status

The Promise of Mutual Recognition

One of the AMDD's long-term goals is mutual recognition of medical device registrations across ASEAN member states — the idea that a registration in one ASEAN country could be recognized by another, reducing duplication and accelerating market access across the region.

As of 2026, full mutual recognition has not been achieved. What exists is a framework of partial harmonization:

• The CSDT is accepted (with national modifications) across most ASEAN countries, providing a common starting point for dossiers.
• Classification principles are harmonized (with notable exceptions like Thailand's three-tier system).
• Post-market surveillance and vigilance requirements are converging but not yet uniform.
• Mutual recognition of registrations remains aspirational. No ASEAN country currently grants automatic recognition of another ASEAN country's device registration.

What Does Work — Bilateral Regulatory Reliance Programs (2025–2026)

While full ASEAN-wide mutual recognition does not exist, 2025–2026 saw a breakthrough in bilateral regulatory reliance programs that deliver concrete, measurable benefits. These represent the most tangible progress toward mutual recognition to date:

Singapore–Malaysia Regulatory Reliance Program:

The MDA and HSA signed an MOU in August 2025 at the 14th ASEAN Medical Device Committee (AMDC) Meeting in Siem Reap, Cambodia. A six-month pilot ran from September 1, 2025 to February 28, 2026, covering Class B, C, and D devices. The pilot was deemed successful, and the reliance pathway has been confirmed as continuing beyond the pilot period. The practical benefits:

Direction	Pathway	Timeline Benefit
Singapore to Malaysia	HSA-registered devices use MDA's Verification route (abridged CAB review)	~30 working days (vs. 60 days standard)
Malaysia to Singapore	MDA-registered devices receive abridged HSA review	Up to 30% shorter evaluation times

HSA clarified that if device classification differs between the two regulators, devices are not within scope. Class D devices with ancillary registrable medicinal products are also excluded.

Malaysia–Thailand Regulatory Reliance Pilot:

Announced December 4, 2025, the Malaysia–Thailand reliance pilot runs from February 1 to April 30, 2026 for Class B, C, and D devices. Thai FDA-approved devices can access Malaysia's Verification pathway, and MDA-registered devices can benefit from expedited Thai FDA review. This follows MDA's addition of Thai FDA to its recognized regulatory authorities list in 2025.

Malaysia–China IVD Regulatory Reliance Program:

The MDA and China's NMPA launched a pilot for IVD devices under an MOU signed in November 2023. Pilot Phase 1 ran from July 30 to September 30, 2025. Key features:

• Malaysian IVD devices gain access to China's "Green Channel" (expedited review, approximately 60 working days)
• Chinese IVD devices can use Malaysia's Verification Pathway (approximately 30 working days)
• Eligibility restricted to manufacturer-owned facilities — third-party brand owners (rebranders, relabelers, assemblers) are excluded
• Limited to Class B, C, and D IVDs with maximum 6 applications per manufacturer in the pilot phase

ASEAN Single Submission Framework Proposal:

In a significant development, a proposal for an ASEAN framework for single submission was accepted in principle by four countries: Malaysia, Singapore, Thailand, and Indonesia. This is on MDA's 2026 agenda and, if implemented, would allow manufacturers to submit a single dossier for review across participating ASEAN markets. This remains at the proposal stage but represents the most ambitious step toward actual mutual recognition since the AMDD was adopted.

Other reliance initiatives in development (2026):

MDA has identified plans for reliance activities with Egypt, Indonesia, Oman, Brazil, India, UAE, and Russia in 2026, while continuing to strengthen reliance programs with China, Singapore, and Thailand. This positions Malaysia as the ASEAN hub for regulatory reliance.

Additional mechanisms that provide practical benefits:

• Reference agency recognition. Many ASEAN NRAs offer expedited or abbreviated review for devices already approved by recognized reference regulatory agencies. Malaysia now recognizes 8 reference authorities. Singapore, Thailand, and the Philippines all offer abridged pathways for reference-approved devices.
• CSDT as a common dossier platform. Building your dossier in CSDT format genuinely reduces the work of multi-country submissions. The modular structure allows you to swap out Chapter 1 (country-specific) while reusing Chapters 3–11 across markets.
• ASEAN harmonization working groups. The ASEAN Medical Device Committee and its working groups continue to advance harmonization initiatives, including common post-market surveillance standards, an updated list of 200+ harmonized borderline products with refined risk classifications, and regional regulatory convergence frameworks.

The Gaps

The gaps between the AMDD vision and current reality include:

• Thailand's classification system does not yet fully align with the AMDD four-class model, though the transition is underway with draft regulations published.
• National requirements on top of the AMDD mean that a CSDT-compliant dossier still needs country-specific modifications.
• Regulatory capacity varies widely. Singapore's HSA (now WHO ML4 recognized) and Malaysia's MDA (MDSAP affiliate member) are well-resourced and experienced. Some other NRAs are still building the institutional capacity to fully implement AMDD requirements.
• No centralized ASEAN device database. Unlike the EU's EUDAMED (however imperfect), ASEAN has no shared database of registered devices, adverse events, or certificates. The single submission framework proposal, if implemented, could change this.
• GMP/QMS assessment is not mutually recognized. Each country may independently assess the manufacturer's quality management system, even if the manufacturer holds ISO 13485 certification and has been audited by other ASEAN NRAs. However, MDA's MDSAP affiliate membership and increasing acceptance of reference agency approvals are steps toward QMS recognition convergence.
• Bilateral reliance programs have eligibility restrictions. Not all devices qualify — classification mismatches, Class D devices with ancillary medicinal products, and third-party brand owner exclusions limit the practical applicability of current reliance pathways.

Single-Country vs. Multi-Country Strategy

A key strategic decision for manufacturers entering ASEAN is whether to pursue a single initial market or register in multiple countries simultaneously.

Single-Country Strategy

Best for: Manufacturers new to ASEAN, companies with limited regulatory resources, devices with uncertain market potential in the region.

Recommended first market: Singapore, for several reasons:

• Shortest and most predictable timelines
• English-language submissions accepted
• HSA's reputation can support subsequent registrations
• Strong reference agency recognition pathway if you have FDA/CE approval
• Transparent regulatory process with clear guidance documents

Approach: Register in Singapore first. Use the experience to refine your CSDT dossier. Then expand to additional markets using Singapore registration as supporting evidence.

Multi-Country Strategy

Best for: Manufacturers with established ASEAN partnerships, devices with strong market demand across multiple countries, companies with regulatory resources to manage parallel submissions.

Recommended approach:

1. Build a master CSDT dossier with all chapters complete.
2. Prepare country-specific Chapter 1 modules for each target market.
3. Engage local representatives in each target country before submission — they will need to obtain the necessary business licenses (Dealer's License in Singapore, MAR in Malaysia, LTO in Philippines, etc.).
4. Submit in parallel where possible, starting with Singapore and one or two additional priority markets.
5. Stagger higher-complexity markets. If Indonesia is a priority but you expect TKDN complications, start that process early while simultaneously pursuing faster markets like Singapore and Malaysia.

Typical Multi-Country Timeline

Phase	Activity	Timeline
Phase 1	Master CSDT dossier preparation	2–4 months
Phase 2	Country-specific adaptations, local representative engagement	1–3 months
Phase 3	Simultaneous submissions (Singapore + 1–2 others)	Parallel submissions
Phase 4	First approvals (Singapore likely first)	3–8 months after submission
Phase 5	Remaining approvals	6–18 months after submission
Phase 6	Expand to additional markets	Ongoing

For a Class C device with US FDA 510(k) clearance and EU CE marking, a reasonable expectation is that you could achieve registration in Singapore within 4–8 months, Malaysia within 6–12 months, and one or two additional ASEAN countries within 9–18 months.

Recent Regulatory Developments (2024–2026)

The ASEAN regulatory landscape is evolving rapidly. 2025 was defined by regulatory reliance initiatives, and 2026 is shaping up as a year of implementation and expansion. Key developments to monitor include:

Bilateral Regulatory Reliance — The Defining Trend of 2025–2026

Regulatory reliance — the concept of regulators leveraging each other's authorization decisions — emerged as the dominant theme across ASEAN in 2025. The Singapore-Malaysia reliance pilot (completed and confirmed permanent), Malaysia-Thailand reliance pilot (February–April 2026), and Malaysia-China IVD pilot represent concrete steps toward the AMDD's vision of reduced regulatory duplication. The ASEAN single submission framework proposal, accepted in principle by Malaysia, Singapore, Thailand, and Indonesia, could fundamentally reshape market access strategy if implemented. Manufacturers should monitor these programs closely and consider whether coordinating submissions across participating countries can reduce timelines and costs.

Indonesia's Regulatory Modernization

Indonesia issued Government Regulation No. 5 of 2024, which replaced the prior regulatory framework for medical devices. Permenkes No. 11 of 2025 further updated business licensing requirements with e-labeling recognition and streamlined the OSS-RBA system. Key ongoing developments include:

• Halal certification enforcement beginning with Class A devices in 2026 under PP No. 42/2024
• CKG program expansion to 130 million screenings in 2026, driving government procurement demand
• REGALKES portal improvements for online product registration
• KFA/e-Catalogue system requirements for government procurement access
• Continued emphasis on local content (TKDN) requirements and domestic manufacturing promotion

Vietnam's Decree 98/2021 Implementation and Fee Reduction

Vietnam's comprehensive revision of its medical device regulatory framework continues to be implemented. Key 2025–2026 developments include:

• 50% fee reduction for medical device registration, effective July 2025 through December 2026
• Crackdown on self-declaration irregularities for Class A/B devices, with MOH seminars emphasizing applicant responsibility for classification accuracy
• Decree 37/2026/ND-CP updating labeling requirements (effective January 2026)
• Indefinite registration validity under Decree 98/2021 (replacing the previous 5-year term)
• Six-group quality classification framework in preparation for 2027 implementation, creating tiered fast-track pathways based on technical standards and quality certification

Thailand's AMDD Alignment and Labeling Reform

Thailand made significant regulatory advances in 2025–2026:

• Four-class AMDD transition: Draft regulations for the AMDD-aligned four-class system have been published. While the three-tier system remains in effect, the transition framework is becoming clearer.
• New labeling regulation B.E. 2568 (2025): Final notification issued December 2025, effective June 20, 2026, with separate requirements for home-use, professional-use, SaMD, and reusable instruments. Two-year transition period through June 2028.
• Electronic change notification system: Launched in 2026 for post-approval amendments to medical device licenses.
• Standalone software recognition: Three notifications in B.E. 2569 (2026) addressing establishment registration for standalone software medical devices.
• Regulatory reliance pilot with Malaysia: February–April 2026 for Class B, C, and D devices.

Malaysia's Expanded Regulatory Role

Malaysia positioned itself as the ASEAN hub for regulatory reliance in 2025–2026:

• Recognized authority list expanded to eight (adding HSA and Thai FDA)
• MDSAP affiliate membership achieved
• Three bilateral reliance programs launched (Singapore, Thailand, China)
• MeDC@St 2.0+ portal enhancements and fully online classification
• Class A fee revision (MYR 500 application + MYR 750 registration, effective January 2026)
• Import permit requirements effective January 2, 2026
• Regulatory sandbox launched for novel medical device technologies
• 2026 plans include reliance activities with Egypt, Indonesia, Oman, Brazil, India, UAE, and Russia

Singapore's Continued Leadership

Singapore reinforced its position as the region's most advanced regulatory environment:

• HSA achieved WHO Maturity Level 4 — first NRA in the world to attain the highest rating for medical device regulation (March 2026)
• SHARE platform replaced MEDICS for all device submissions (July 2025)
• Cybersecurity Labelling Scheme (CLS(MD)) operational since October 2024 with 47 devices evaluated
• Expanded economic role aligning regulatory approval with health technology assessment and clinical development for priority disease areas
• SaMD guidance GL-04 Revision 4 (December 2025) with Predetermined Change Management Plan (CMP) pathway and ML-enabled device guidance
• GN-21 Revision 6 (July 2025) updating change notification processes with MLMD-specific flowcharts

Philippines' AMDD Alignment Progress

The Philippines continued its transition toward full AMDD alignment:

• Draft IVD regulation with Certificate of IVD Registration (CIVDR) framework, targeted for 2026
• Draft MDSW guidelines for medical device software classification and registration
• Draft device grouping guidelines allowing multiple devices under a single registration
• PMAS adoption (Administrative Order No. 2025-0030) implementing AMDD Annex 5 post-market surveillance requirements
• Fee suspension extended through 2025–2026

ASEAN Post-Market Surveillance Harmonization

The ASEAN Medical Device Committee has been advancing harmonization of post-market surveillance and vigilance requirements across member states. The Philippines' adoption of AMDD Annex 5 PMAS requirements is a concrete example. The updated list of 200+ harmonized borderline products with refined risk classifications supports consistent interpretation across the region. Initiatives include common adverse event reporting formats and regional information-sharing mechanisms. Progress has been incremental but is accelerating.

Software as a Medical Device (SaMD) in ASEAN

SaMD regulation across ASEAN reached a new level of maturity in 2025–2026:

• Singapore (HSA): Most advanced — GL-04 Revision 4 guidance covers the total product lifecycle, including CMP pathway for pre-approved changes, cybersecurity requirements for SaMD, and ML-enabled device classification guidance.
• Thailand: Issued three B.E. 2569 (2026) notifications for standalone software registration. New labeling rules include SaMD-specific electronic labeling requirements.
• Philippines: Draft MDSW guidelines released for public consultation, covering SaMD and SiMD classification, registration, and renewal.
• Malaysia: E-labeling and digital health on MDA's 2026 roadmap. MDA's regulatory sandbox may accommodate SaMD innovations.
• Indonesia and Vietnam: Earlier stages of SaMD framework development. Expect the most clarity in Singapore, Malaysia, and Thailand, and more uncertainty in other markets.

Increased Focus on Cybersecurity

Following global trends and IMDRF guidance (N88 — Good Machine Learning Practice, N81 — Software-Specific Risk Characterization), ASEAN regulators have intensified cybersecurity requirements:

• Singapore: CLS(MD) operational with four-level cybersecurity labeling. HSA GL-04 R4 includes comprehensive cybersecurity lifecycle requirements covering secure design principles, vulnerability scanning, penetration testing, and end-of-support OS management. Devices with unsupported operating systems that present unmitigable cybersecurity risks will not be permitted for supply in Singapore.
• Other ASEAN markets are expected to follow Singapore's lead. If your device is a connected device, be prepared for cybersecurity questions as part of the registration review across the region.

Tips for Foreign Manufacturers Entering ASEAN

1. Start with Your Regulatory Strategy, Not Your Market Strategy

The most common mistake is choosing ASEAN markets based purely on commercial opportunity without understanding the regulatory requirements and timelines. Indonesia is the largest market, but it is also among the most complex and time-consuming to register in. Build your ASEAN regulatory strategy first, then align your commercial strategy to the regulatory timeline.

2. Choose Local Partners Carefully

In every ASEAN country, you need a local partner — whether called a Dealer, Authorized Representative, or importer. This partner becomes the legal face of your product in that market. A poor local partner can delay your registration by months or years. Evaluate potential partners based on:

• Regulatory experience (how many devices have they successfully registered?)
• Commercial capability (can they actually sell and distribute your product?)
• Financial stability (will they be around for the 5-year registration validity period?)
• Responsiveness (how quickly do they respond to regulatory queries from the NRA?)

3. Build a CSDT-Structured Master Dossier

Even if your first ASEAN market is Singapore and you could submit a simpler dossier, invest in building a comprehensive CSDT-structured master dossier. The incremental effort is modest, and the payoff when you expand to additional countries is substantial.

4. Leverage Reference Agency Approvals

If you have US FDA clearance/approval, EU CE marking, or approvals from other recognized reference agencies (TGA, Health Canada, PMDA), lead with these in your ASEAN submissions. Most ASEAN NRAs offer some form of expedited review for devices with reference agency approvals. Include your FDA clearance letters, CE certificates, and Declarations of Conformity prominently in your dossier.

5. Budget for Translation

Thailand, Indonesia, and Vietnam have language requirements that can add significant cost and time. Budget for certified translations early and factor translation timelines into your registration schedule.

6. Plan for Post-Market Obligations from Day One

Your obligations do not end with registration. Every ASEAN country requires adverse event reporting, and you need a system in place to collect, assess, and report post-market safety data. If you do not have a post-market surveillance system that covers ASEAN, build one before you register — not after.

7. Monitor Regulatory Changes Continuously

ASEAN regulatory environments are in active evolution. What you learn today about Indonesian, Vietnamese, or Thai requirements may change in 6–12 months. Subscribe to regulatory intelligence services that cover ASEAN, attend ASEAN medical device regulatory conferences (RAPS and GMTA host regular ASEAN-focused sessions), and maintain ongoing dialogue with your local representatives about regulatory developments.

8. Understand the Commercial Landscape

Registration is only one piece of the puzzle. Understanding reimbursement systems, hospital procurement processes (particularly government hospital procurement, which is dominant in many ASEAN markets), distribution logistics, and import requirements is essential for translating a registration into actual market access.

9. Do Not Underestimate Free Sale Certificates

Most ASEAN countries require a Free Sale Certificate (FSC) or Certificate of Free Sale (CFS) from the country of manufacture as part of the registration dossier. Obtain these from your home country's regulatory authority before you start ASEAN submissions. Some countries require the FSC to be notarized or legalized by the destination country's embassy. Build this into your timeline.

10. Consider MDSAP Certification

The Medical Device Single Audit Program (MDSAP) is not directly recognized in ASEAN, but having MDSAP certification (which covers the US, Canada, Australia, Brazil, and Japan) demonstrates robust QMS compliance and can support your ASEAN submissions. Some ASEAN NRAs view MDSAP certification favorably, even if they do not formally recognize it as a substitute for their own assessment.

ASEAN Market Size and Opportunity

For manufacturers evaluating the investment required for ASEAN registration, understanding the market opportunity helps contextualize the cost and complexity.

Country	Population (2025 est.)	Healthcare Spend (% of GDP)	Medical Device Market Size (est. 2025)	Growth Rate (CAGR)
Indonesia	280 million	~3.4%	USD 3.0–3.5 billion	10–12%
Thailand	72 million	~4.4%	USD 2.5–3.0 billion	8–10%
Vietnam	100 million	~5.5%	USD 1.5–2.0 billion	12–15%
Philippines	115 million	~4.7%	USD 1.5–2.0 billion	10–12%
Malaysia	34 million	~4.5%	USD 1.5–2.0 billion	7–9%
Singapore	6 million	~4.5%	USD 1.0–1.5 billion	5–7%

Key market characteristics:

• Import dependency is high. Most ASEAN countries import 80–95% of their medical devices. This is both an opportunity (large addressable market for foreign manufacturers) and a risk (governments are increasingly promoting domestic manufacturing).
• Government healthcare is dominant. In Indonesia, Thailand, the Philippines, and Vietnam, government hospitals and universal healthcare programs represent the majority of device demand. Understanding government procurement processes is essential.
• Private sector is growing. Private hospital chains are expanding across the region, particularly in Thailand, Malaysia, Singapore, and Vietnam. The private sector often adopts new technologies faster and may have different procurement processes than government hospitals.
• Medical tourism is a significant driver in Thailand, Singapore, and Malaysia. Hospitals serving medical tourism patients demand advanced devices and are often early adopters.

Conclusion

Medical device registration in Southeast Asia requires navigating a landscape that is simultaneously harmonizing and fragmented. The AMDD provides a common framework and the CSDT gives you a shared dossier structure, but each country maintains its own regulatory authority, its own requirements, and its own timeline.

The six markets covered in this guide — Singapore, Malaysia, Thailand, Indonesia, the Philippines, and Vietnam — represent the vast majority of ASEAN medical device demand. Singapore offers the most predictable and efficient registration process and is the recommended starting point for manufacturers new to the region. Malaysia is a strong second market with a mature regulatory system. Thailand, Indonesia, the Philippines, and Vietnam each present significant commercial opportunities but require more investment in local partnerships, translation, and regulatory navigation.

The keys to success in ASEAN are: a well-structured CSDT master dossier, strong local partners in each target market, reference agency approvals (particularly US FDA and EU CE marking) that can accelerate reviews, and a commitment to monitoring and adapting to regulatory changes that are ongoing across the region.

Southeast Asia is not a market you enter casually. But for manufacturers willing to invest in understanding the regulatory landscape and building the right partnerships, the region offers substantial and growing commercial opportunity in a part of the world where healthcare infrastructure investment is accelerating and demand for quality medical devices is rising.